Altimmune to Participate in Stifel Cardiometabolic Forum
Globe Newswire•23/09/2026•08:00 ET
0
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
A webcast of the fireside chat will be available via the Events section of the Altimmune website.
Get started
Create a free account to read the full story and Whiz Insights.